Clinical aspects of urogenital atrophy in women

Grzegorz Stachowiak; Tomasz Pertyński

eISSN: 2299-0038
ISSN: 1643-8876

Menopause Review/Przegląd Menopauzalny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

1/2011
vol. 10

Send email

Copy url:

abstract:

Review paper

Clinical aspects of urogenital atrophy in women

Grzegorz Stachowiak

,

Tomasz Pertyński

Przegląd Menopauzalny 2011; 1: 1–4

Online publish date: 2011/03/16

View full text Get citation

Female urogenital atrophy increases with the menopausal age. It is also susceptible to various types of hormonal therapy, e.g. systemic menopausal hormonal therapy and vaginal hormone therapy. Tibolone,

a synthetic steroid with the affinity to all the basic types of steroid receptors – oestrogen, progesterone and androgen, is a good (i.e. effective and safe) alternative option to other therapies of atrophic lesions of the lower urogenital tract in women.

keywords:

Clinical aspects of urogenital atrophy in women

Grzegorz Stachowiak , Tomasz Pertyński

menopause, urogenital atrophy, hormonal therapy, tibolone

Grzegorz Stachowiak

,

Tomasz Pertyński